Skip to main content
. Author manuscript; available in PMC: 2018 Nov 2.
Published in final edited form as: Oncogene. 2018 May 2;37(31):4226–4238. doi: 10.1038/s41388-018-0274-4

Figure 4. Confirmation of HTS hits.

Figure 4

The ability of some of the compounds identified in the HTS were confirmed by 96-well plate assay to both (a, c, e) activate reporter activity in clone SB01 (SABRE ON) as well as (b, d, f) suppress reporter activity in clone SB03 (SABRE OFF). Error bars ± SD. (g) Treatment of SB01 cells for 24 hours with 1uM of each indicated drug results in decreased ERK1/2 phosphorylation as determined by Western blot analysis (20ug per lane).